LogicBio Therapeutics

Company Overview

Snapshot

Founded in January 2016 by Adi Barzel and Mark Kay, LogicBio Therapeutics operated with 11–50 employees. The company raised $119M across 3 funding rounds from 5 investors, including OrbiMed. In October 2018, LogicBio Therapeutics completed an Initial Public Offering on NASDAQ.

Business overview

LogicBio Therapeutics is a Health Tech & Life Sciences company focused on developing gene therapy vectors for previously incurable genetic and infectious diseases, such as hemophilia, HIV/AIDS, and methylmalonic acidemia. The company's core technology utilizes a proprietary nonpathogenic adeno-associated viral vector, designed to offer improved efficiency and safety for treating both children and adults. LogicBio Therapeutics operates within the Pharmaceuticals sector, specifically targeting drug discovery and development for rare diseases.

Strategic signal

In February 2019, LogicBio Therapeutics ceased operations, leading to its delisting from NASDAQ. This event signals a complete cessation of the company's activities, indicating a significant and permanent shift in its market presence and strategic trajectory.

Company Intelligence Q&A

What was the outcome of LogicBio Therapeutics' public offering?

In February 2019, LogicBio Therapeutics was delisted from NASDAQ due to ceasing operations.

When did LogicBio Therapeutics conduct its Initial Public Offering?

LogicBio Therapeutics completed its Initial Public Offering on NASDAQ in October 2018, raising $70M.

Which investors participated in LogicBio Therapeutics' Series B funding round?

In June 2017, LogicBio Therapeutics received funding from Arix Bioscience and Pontifax.

Who were the founders of LogicBio Therapeutics?

LogicBio Therapeutics was founded by Adi Barzel and Mark Kay.

What is LogicBio Therapeutics' primary focus?

LogicBio Therapeutics focuses on developing gene therapy vectors for previously incurable genetic and infectious diseases, such as hemophilia, HIV/AIDS, and methylmalonic acidemia.